What did Coalesce Capital pay for Examinetics?

Coalesce Capital acquired Examinetics for $150.0M in 2023 (15.0x EBITDA), equivalent to 2.90x revenue. Target revenue was approximately $51.0M. Target EBITDA was approximately $10.0M.

What does Examinetics do?

Examinetics is a urgent care business.

What multiple did Coalesce Capital pay for Examinetics?

15.0x EBITDA and 2.90x revenue, based on disclosed deal value of $150.0M and disclosed financials.

M&A TRANSACTION · 2023

Examinetics acquired by Coalesce Capital

$150.0M· 15.0x EBITDA· 2.90x revenue

Target

Examinetics

Acquirer

Coalesce Capital

Disclosed financials at time of acquisition

Revenue

$51.0M

EBITDA

$10.0M

Deal Value

$150.0M

EV/EBITDA

15.0x

Context

This $150.0M acquisition of Examinetics by Coalesce Capital sits in the urgent care sub-vertical. The 15.0x EBITDA multiple paid in 2023 can be compared against the population median for urgent care transactions of similar size on our Urgent Care valuation hub.

Source

Data sourced from Press reporting. All figures reflect disclosed values at the time of the acquisition; no estimated or imputed data. Methodology

Value your own urgent care

Get an instant valuation range for your business. Backed by 25,592 real M&A transactions.

Compare your business to the Examinetics acquisition.

Citation: ExitValue.ai. (2023). Examinetics acquired by Coalesce Capital. https://exitvalue.ai/deals/examinetics-acquired-by-coalesce-capital-hc-2023-0042